Altre lingue Oncolytics Biotech Inc.

Azioni

ONC

CA6823108759

Mercato chiuso - Toronto S.E. Altri mercati azionari 21:59:30 18/04/2024			Variaz. 5gg	Var. 1 gen.
1,43 ^CAD	-0,69%		-10,06%	-20,11%

11/04	Oncolytics Biotech Inc. annuncia la presentazione di una richiesta di incontro di tipo C alla FDA	CI
08/03	RBC ribadisce le prospettive positive per Oncolytics -- Mantiene il target di 6 dollari, il rating Outperform/rischio speculativo	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Oncolytics Biotech : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 15, 2024 MANAGEMENT INFORMATION CIRCULAR - Form 6-K	12/04
Oncolytics Biotech Advances toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA	12/04
Oncolytics Biotech Inc. Announces the Submission of a Type C Meeting Request to the FDA	11/04
Oncolytics Biotech Down 1.8% In US Premarket As Submits Type C Meeting Request to FDA	11/04
Oncolytics Biotech Brief: Advancing Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA	11/04
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA	11/04
Oncolytics Biotech to participate in a Panel Presentation at Canaccord Genuity s Horizons in Oncology Virtual Conference	03/04
RBC Reiterates Positive Outlook For Oncolytics -- Maintains $6 Target, Outperform/Speculative Risk Rating	08/03
Oncolytics Biotech Up 2.9% as Its Fourth-Quarter Loss Narrows on a One-Time Gain	07/03
Oncolytics Biotech Brief: Q4 Net loss for the fourth quarter of 2023 was $3.9 million	07/03
Oncolytics Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
North American Morning Briefing : Powell Still in the Spotlight; ECB Rate Decision Looms	07/03
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning	06/03
Oncolytics Biotech Inc. Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN	05/03
Oncolytics Biotech Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN	05/03
Oncolytics Biotech Brief: Says Filed Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN	05/03
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights	04/03
Oncolytics Biotech Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference	29/02
Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments	15/02
Oncolytics Biotech Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort	15/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Oncolytics Biotech Inc.

Azioni

ONC

CA6823108759

Altre lingue

Filtri